CLAIMS:

1. A compound of formula I:



I

wherein n is 1 or 2;

R^1 represents CF_3 or C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-9}cycloalkyl or C_{3-6}cycloalkylC_{1-6}alkyl, any of which may bear up to 2 substituents selected from halogen, CN, CF_3, OR^3, COR^3, CO_2R^3, $OCOR^4$, SO_2R^4, $N(R^5)_2$, and $CON(R^5)_2$,

or R^1 represents aryl, arylC_{1-6}alkyl, C-heterocyclyl or C-heterocyclylC_{1-6}alkyl;

R^2 represents H or C_{1-4}alkyl;

R^3 represents H, C_{1-4}alkyl, phenyl or heteroaryl;

R^4 represents C_{1-4}alkyl, phenyl or heteroaryl;

R^5 represents H or C_{1-4}alkyl, or two R^5 groups together with a nitrogen atom to which they are mutually attached complete an azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine or thiomorpholine-1,1-dioxide ring;

Ar^1 and Ar^2 independently represent phenyl or heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CN, NO_2, CF_3, CHF_2, OH, OCF_3, CHO, CH=NOH, C_{1-4}alkoxy, C_{1-4}alkoxycarbonyl, C_{2-6}acyl, C_{2-6}alkenyl and C_{1-4}alkyl which optionally bears a substituent selected from halogen, CN, NO_2, CF_3, OH and C_{1-4}alkoxy;

aryl at every occurrence thereof refers to phenyl or heteroaryl which optionally bear up to 3 substituents selected from halogen, CN, NO_2, CF_3, OCF_3, OR^3, COR^3, CO_2R^3, $OCOR^4$, $N(R^5)_2$, $CON(R^5)_2$ and optionally-substituted C_{1-6}alkyl, C_{1-6}alkoxy, C_{2-6}alkenyl or C_{2-6}alkenyloxy wherein the substituent is selected from halogen, CN, CF_3, phenyl, OR^3, CO_2R^3, $OCOR^4$, $N(R^5)_2$ and $CON(R^5)_2$; and

C-heterocyclyl and N-heterocyclyl at every occurrence thereof refer respectively to a heterocyclic ring system bonded through carbon or nitrogen, said ring system being non-aromatic and comprising up to 10 atoms, at least one of which is O, N or S, and optionally bearing up to 3 substituents selected from oxo, halogen, CN, NO_2, CF_3, OCF_3, OR^3, COR^3, CO_2R^3, $OCOR^4$, OSO_2R^4, $N(R^5)_2$, $CON(R^5)_2$ and optionally-substituted phenyl, C_{1-6}alkyl, C_{1-6}alkoxy, C_{2-6}alkenyl or C_{2-6}alkenyloxy wherein the substituent is selected from halogen, CN, CF_3, OR^3, CO_2R^3, $OCOR^4$, $N(R^5)_2$ and $CON(R^5)_2$;

or a pharmaceutically acceptable salt thereof.

2. A compound according to Claim 1 wherein Ar^1 is 6-trifluoromethyl-3-pyridyl, 4-chlorophenyl or 4-trifluoromethylphenyl and Ar^2 is 2,5-difluorophenyl.

3. A compound according to Claim 1 of formula II:



II

wherein X represents N or CH;

R^6 represents H, F, Cl, Br, CN, CF_3, $CH{=}CH_2$ or CH_3;

R^7 represents F, Cl, Br, CN, CH_3 or CH_2OH; and

R^1 is as defined in claim 1;

or a pharmaceutically acceptable salt thereof.

4. A compound according to Claim 3 wherein R^1 is CF_3.

5. The compound according to Claim 4 which is trifluoromethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(6-trifluoromethyl-pyridine-3-sulfonyl)-cyclohexyl]-amide or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound according to Claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

7. A method of treatment of a subject suffering from or prone to a condition associated with the deposition of β-amyloid which comprises administering to the subject an effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

8. The method according to Claim 7 wherein the condition is Alzheimer's disease.

9. A process for preparing a compound according to Claim 1 in which R^2 is H comprising reacting a sulfinylchloride R^1SOCl or a sulfonyl chloride R^1SO_2Cl or a sulfonic anhydride $(R^1SO_2)_2O$ with an amine of formula III:



III

wherein R^1, Ar^1 and Ar^2 are as defined in Claim 1.